Compare PXED & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PXED | CTMX |
|---|---|---|
| Founded | 1976 | 2008 |
| Country | United States | United States |
| Employees | 3400 | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 977.1M |
| IPO Year | N/A | 2015 |
| Metric | PXED | CTMX |
|---|---|---|
| Price | $28.92 | $3.66 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 10 |
| Target Price | ★ $44.29 | $12.10 |
| AVG Volume (30 Days) | 76.0K | ★ 2.9M |
| Earning Date | 04-07-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.07% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | ★ $76,201,000.00 |
| Revenue This Year | $3.85 | N/A |
| Revenue Next Year | $4.49 | $7.61 |
| P/E Ratio | ★ $11.20 | $22.58 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $23.52 | $1.72 |
| 52 Week High | $38.19 | $8.21 |
| Indicator | PXED | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 47.46 | 35.45 |
| Support Level | $28.40 | $3.39 |
| Resistance Level | $30.85 | $3.91 |
| Average True Range (ATR) | 1.39 | 0.21 |
| MACD | -0.05 | -0.03 |
| Stochastic Oscillator | 23.37 | 24.61 |
Phoenix Education Partners Inc. is a mission-driven organization operating at the forefront of the rapidly evolving post-secondary education market. it is an online education provider and a pioneer in its field. The company benefits from the dynamic interplay between technological innovation, education, employment, and economic trends. It is focused on delivering personalized, career-relevant, and affordable education to its students through its flexible learning model, skills-aligned curriculum, and accessible tuition costs.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.